SLC17A6 and Parkinson disease: Considering the reported efficacy of group III mGluR agonists in improving motor symptoms in Parkinson’s disease animal models52, astrocyte VGLUT2-dependent signalling represents a potential therapeutic target for Parkinson’s disease.